INOS-selective inhibitors for cancer prevention: Promise and progress

Future Medicinal Chemistry

Volumn 4, Issue 17, 2012, Pages 2193-2204

  Janakiram, Naveena B ^a   Rao, Chinthalapally V ^a  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE DERIVATIVE; CYCLOOXYGENASE 2; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ESTROGEN; FLAVINE ADENINE NUCLEOTIDE; FLAVINE MONONUCLEOTIDE; GUANIDINE DERIVATIVE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; N(G) NITROARGININE METHYL ESTER; N(G),N(G) DIMETHYLARGININE; NEURONAL NITRIC OXIDE SYNTHASE; NITRATE; NITRITE; NONSTEROID ANTIINFLAMMATORY AGENT; OXIDIZED LOW DENSITY LIPOPROTEIN RECEPTOR 1; OXYGENASE INHIBITOR; TETRAHYDROBIOPTERIN; UREA DERIVATIVE; WNT PROTEIN;

ABERRANT CRYPT FOCUS; ANTINEOPLASTIC ACTIVITY; BLADDER CANCER; CANCER PREVENTION; COLON ADENOCARCINOMA; COLON ADENOMA; COLON CANCER; COLON CARCINOGENESIS; ESOPHAGUS CANCER; GENE OVEREXPRESSION; HEAD AND NECK CANCER; HUMAN; INTRADUCTAL CARCINOMA; MELANOMA; NITROSYLATION; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROTEIN EXPRESSION; REVIEW; SKIN CANCER; TUMOR GROWTH; WNT SIGNALING PATHWAY;

ANIMALS; ENZYME INHIBITORS; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; NITRIC OXIDE; NITRIC OXIDE DONORS; NITRIC OXIDE SYNTHASE TYPE II; S-NITROSOTHIOLS; SIGNAL TRANSDUCTION;

EID: 84870426866     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.12.168     Document Type: Review

References (129)

1. Moller MN, Lancaster JR, Denicola A Jr. The interaction of reactive oxygen and nitrogen species with membranes. Curr. Top. Membr. 61, 23-42 (2008).
2. Fukumura D, Kashiwagi S, Jain RK. The role of nitric oxide in tumour progression. Nat. Rev. Cancer 6, 521-534 (2006).
3. Ambs S, Merriam WG, Bennett WP et al. Frequent nitric oxide synthase-2 expression in human colon adenomas: implication for tumor angiogenesis and colon cancer progression. Cancer Res. 58, 334-341 (1998).
4. Takahashi M, Fukuda K, Ohata T, Sugimura T, Wakabayashi K. Increased expression of inducible and endothelial nitric oxide synthases in rat colon tumors induced by azoxymethane. Cancer Res. 57, 1233-1237 (1997).
5. Rao CV, Kawamori T, Hamid R, Reddy BS. Chemoprevention of colonic aberrant crypt foci by an inducible nitric oxide synthase-selective inhibitor. Carcinogenesis 20, 641-644 (1999).
6. Rao CV, Cooma I, Simi B, Manning PT, Connor JR, Reddy BS. Chemopreventive properties of a selective inducible nitric oxide synthase inhibitor in colon carcinogenesis, administered alone or in combination with celecoxib, a selective cyclooxygenase-2 inhibitor. Cancer Res. 62, 165-170 (2002).
7. Gow AJ, Chen Q, Hess DT, Day BJ, Ischiropoulos H, and Stamler JS. Basal and stimulated protein S-nitrosylation in multiple cell types and tissues. J. Biol. Chem. 277, 9637-9640 (2002).
8. Hess DT, Matsumoto A, Kim SO, Marshall HE, Stamler JS. Protein S-nitrosylation: purview and parameters. Nat. Rev. Mol. Cell Biol. 6, 150-166 (2005).
9. Foster MW, McMahon TJ, Stamler JS. S-nitrosylation in health and disease. Trends Mol. Med. 9, 160-168 (2003).
10. Moncada S, Palmer RM, Higgs EA. Nitric oxide: physiology pathophysiology and pharmacology. Pharmacol Rev. 43, 109-142 (1991).
11. Cohen RA, Vanhoutte PM. Endothelium-dependent hyperpolarization-beyond nitric oxide and cyclic GMP. Circulation 92, 3337-3349 (1995).
12. Lehninger A. Principles of Biochemistry (3rd Edition). Sarvier, São Paulo, Brazil (2002).
13. Michel T, Feron O. Nitric oxide synthases: which, where, how, and why? J. Clin. Invest. 100(9), 2146-2152 (1997).
14. Palmer RMJ, Ashton DS, Moncada S. Vascular endothelial cells synthesize nitric oxide from L-arginine. Nature 333, 664-666 (1988).
15. Bredt DS, Hwang PM, Glatt CE, Lowenstein C, Reed RR, Snyder SH. Cloned and expression nitric oxide synthase structurally resembles cytocrome P-450 reductase. Nature 351, 714-718 (1991).
16. Crane BR, Arvai AS, Gachhui R et al. The structure of nitric oxide synthase oxygenase domain and inhibitor complexes. Science 278(5337), 425-431 (1997).
17. Crane BR, Arvai AS, Ghosh DK et al. Structure of nitric oxide synthase oxygenase dimer with pterin and substrate. Science 279(5359), 2121-2126 (1998).
18. Bruckdorfer R. The basics about nitric oxide. Mol. Aspects Med. 26, 3-31 (2005).
19. Schulz R, Triggle CR. Role of NO in vascular smooth muscle and cardiac muscle function. Trends Pharmacol. Sci. 15, 255-259 (1994).
20. Dominiczack AF, Bohr DF. Nitric oxide and its putative role in hypertension. Hypertension 25, 1202-1211 (1995).
21. Tibiriça E. Fisiopatologia em Medicina Cardiovascular. Revinter, Rio de Janeiro, Brazil (2001).
22. Govoni M, Jansson EA, Weitzberg E, Lundberg JO. The increase in plasma nitrite after a dietary nitrate load is markedly attenuated by an antibacterial mouthwash. Nitric Oxide 19(4), 333-337 (2008).
23. Cosby K, Partovi KS, Crawford JH et al. Nitrite reduction to nitric oxide by deoxyhemoglobin vasodilates the human circulation. Nat. Med. 9(12), 1498-1505 (2003).
24. Maekawa A, Ogiu T, Onodera H et al. Carcinogenicity studies of sodium nitrite andsodium nitrate in F-344 rats. Food Chem. Toxicol. 20 (1), 25-33 (1982).
25. Preston-Martin S. N-Nitroso compounds and childhood brain tumors: a case-control study. Cancer Res. 42(12), 5240-5245 (1982).
26. Preston-Martin S. Maternal consumption of cured meats and vitamins in relation to pediatric brain tumors. Cancer Epidemiol. Biomarkers Prev. 5(8), 599-605 (1996).
27. Ward MH. Dietary exposure to nitrite and nitrosamines and risk of nasopharyngeal carcinoma in Taiwan. Int. J. Cancer. 86(5), 603-609 (2000).
28. Pogoda JM, Preston-Martin S. Maternal cured meat consumption during pregnancy and risk of paediatric brain tumour in offspring: potentially harmful levels of intake. Public Health Nutr. 4(2), 183-189 (2001).
29. Sarasua S, Savitz DA. Cured and broiled meat consumption in relation to childhood cancer: Denver, Colorado (United States). Cancer Causes Control 5(2), 141-148 (1994).
30. McCredie M. Antenatal risk factors for malignant brain tumors in New South Wales children. Int. J. Cancer. 56(1), 6-10 (1994).
31. Volkmer BG. Influence of nitrate levels in drinking water on urological malignancies: a community-based cohort study. Br. J. Urol. Int. 95(7), 972-976 (2005).
32. Takahashi M, Mutoh M, Kawamori T, Sugimura T, Wakabayashi K. Altered expression of b-catenin, inducible nitric oxide synthase and cyclooxygenase-2 in azoxymethane-induced rat colon carcinogenesis. Carcinogenesis 21, 1319-1327 (2000).
33. Thun MJ, Henley SJ, Patrono C. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J. Natl Cancer Inst. 94, 252-266 (2002).
34. Ahn B, Ohshima H. Suppression of intestinal polyposis in Apc(Min/+) mice by inhibiting nitric oxide production. Cancer Res. 61, 8357-8360 (2001).
35. Kojima M, Morisaki T, Tsukahara Y et al. Nitric oxide synthase expression and nitric oxide production in human colon carcinoma tissue. J. Surg. Oncol. 70, 222-229 (1999).
36. Yagihashi N, Kasajima H, Sugai S et al. Increased in situ expression of nitric oxide synthase in human colorectal cancer. Virch. Arch. 436, 109-114 (2000).
37. Vakkala M, Kahlos K, Lakari E, Paakko P, Kinnula V, Soini Y. Inducible nitric oxide synthase expression, apoptosis, and angiogenesis in in situ and invasive breast carcinomas. Clin. Cancer Res. 6, 2408-2416 (2000).
38. Tschugguel W, Schneeberger C, Unfried G et al. Expression of inducible nitric oxide synthase in human breast cancer depends on tumor grade. Breast Cancer Res. Treat. 56, 145-151 (1999).
39. De Paepe B, Verstraeten VLRM, De Potter CR, Bullock GR. Increased angiotensin II type-2 receptor density in hyperplasia, DCIS and invasive carcinoma of the breast is paralleled with increased iNOS expression. Histochem. Cell Biol. 117, 13-19 (2002).
40. Aaltomaa SH, Lipponen PK, and Kosma V-M. Inducible nitric oxide synthase (iNOS) expression and its prognostic value in prostate cancer. Anticancer Res. 21, 3101-3106 (2001).
41. Uotila P, Valve E, Martikainen P, Nevalainen M, Nurmi M, Harkonen P. Increased expression of cyclooxygenase-2 and nitric oxide synthase-2 in human prostate cancer. Urol. Res. 29, 23-28 (2001).
42. Aaltomaa SH, Lipponen PK, Viitanen J, Kankkunen J-P, Ala-Opas MY, Kosma V-M. The prognostic value of inducible nitric oxide synthase in local prostate cancer. Br. J. Urol. Int. 86, 234-239 (2000).
43. Klotz T, Bloch W, Volberg C, Engelmann U, Addicks K. Selective expression of inducible nitric oxide synthase in human prostate carcinoma. Cancer 82, 1897-1903 (1998).
44. Baltaci S, Orhan D, Gogus C, Turkolmez K, Tulunay O, Gogus O. Inducible nitric oxide synthase expression in benign prostatic hyperplasia, low-and high-grade prostatic intraepithelial neoplasia and prostatic carcinoma. Br. J. Urol. Int. 88, 100-103 (2001).
45. Swana HS, Smith SD, Perrotta PL, Saito N, Wheeler MA, Weiss RM. Inducible nitric oxide synthase with transitional cell carcinoma of the bladder. J. Urol. 161, 630-634 (1999).
46. Hayashi H, Kuwahara M, Fujisaki N, Furihata M, Ohtsuki Y, Kagawa S. Immunohistochemical findings of nitric oxide synthase expression in urothelial transitional cell carcinoma including dysplasia. Oncol. Rep. 8, 1275-1279 (2001).
47. Wolf H, Haeckel C, Roessner A. Inducible nitric oxide synthase expression in human urinary bladder cancer. Virch. Arch. 437, 662-666 (2000).
48. Klotz T, Bloch W, Jacobs G, Niggemann S, Engelmann U, Addicks K. Immunolocalization of inducible and constitutive nitric oxide synthases in human bladder cancer. Urology 54, 416-419 (1999).
49. Brennan PA, Conroy B, Spedding AV. Expression of inducible nitric oxide synthase and p53 in oral epithelial dysplasia. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 90, 624-629 (2000).
50. Brennan PA, Umar T, Smith GI, Lo CH, Tant S. Expression of nitric oxide synthase-2 in cutaneous squamous cell carcinoma of the head and neck. Br. J. Oral Maxillofac. Surg. 40, 191-194 (2002).
51. Wilson KT, Fu S, Ramanujam KS, Meltzer SJ. Increased expression of inducible nitric oxide synthase and cyclooxygenase-2 in Barrett's esophagus and associated adenocarcinomas. Cancer Res. 58, 2929-2934 (1998).
52. Jaffrey SR, Erdjument-Bromage H, Ferris CD, Tempst P, Snyder SH. Protein S-nitrosylation: a physiological signal for neuronal nitric oxide. Nat. Cell Biol. 3, 193-197 (2001).
53. Jesus-Berrios MD, Liu L, Nussbaum JC, Cox GM, Stamler JS, Heitman J. Enzymes that counteract nitrosative stress promote fungal virulence. Curr. Biol. 13, 1963-1968 (2003).
54. Liu L. Essential roles of S-nitrosothiols in vascular homeostasis and endotoxic shock. Cell 116, 617-628 (2004).
55. Stamler JS, Jia L, Eu JP et al. Blood flow regulation by S-nitrosohemoglobin in the physiological oxygen gradient. Science 276, 2034-2037 (1997).
56. Eu JP, Sun J, Xu L, Stamler JS, Meissner G. The skeletal muscle calcium release channel: coupled O2 sensor and NO signaling functions. Cell 102, 499-509 (2000).
57. Lai TS, Hausladen A, Slaughter TF, Eu JP, Stamler JS, Greenberg CS. Calcium regulates S-nitrosylation, denitrosylation, and activity of tissue transglutaminase. Biochemistry 40, 4904-4910 (2001).
58. Singel DJ, Stamler JS. Chemical physiology of blood flow regulation by red blood cells: role of nitric oxide and S-nitrosohemoglobin. Annu. Rev. Physiol. 67, 99-145 (2005).
59. Stamler JS, Lamas S, Fang FC. Nitrosylation: the prototypic redox-based signaling mechanism. Cell 106, 675-683 (2001).
60. Mannick JB, Schonhoff C, Papeta N et al. Nitrosylation of mitochondrial caspases. J. Cell Biol. 20(3), 245-248 (2001).
61. Lechner M, Lirk P, Rieder J. Inducible nitric oxide synthase (iNOS) in tumor biology: the two sides of the same coin. Semi. Cancer Biol. 15 (4), 277-289.
62. Rossig L, Fichtlscherer B, Breitschopf K et al. Nitric oxide inhibits caspase-3 by S-nitrosation in vivo. J. Biol. Chem. 274 6823-6828 (1999).
63. Nguyen T, Brunson D, Crespi CL, Penman BW, Wishnok JS, Tannenbaum SR. DNA damage and mutation in human cells exposed to nitric oxide in vivo. Proc. Natl Acad. Sci. USA 89, 3030-3034 (1992).
64. Wink DA, Vodovotz Y, Laval J, Laval F, Dewhirst MW, Mitchell JB. Multifaceted role of iNOS in cancer. Carcinogenesis 19, 711-721 (1998).
65. Morita EH, Ohkulo T, Kuroka I, Shikawa M, Tanaka K, Morikawa K. Implications of the zinc finger motif found in the DNA binding domain of the human XPA protein genes. Cell 1(5), 437-442 (1996).
66. Jiaswal M, Larusso NF, Nishioka N, nakabeppu Y, Gores GJ. Human ogg1, a protein involved in the repair of 8-oxoguanine is inhibited by nitric oxide. Cancer Res. 61(17), 6388-6393 (2001).
67. Parvin S, Singh R, Hernandez E, Wu G, Chaudhuri G. Nitric oxide in physiologic concentrations targets the translational machinery to increase the proliferation of human breast cancer cells: involvement of mammalian target of rapamycin/eIF4E pathway. Cancer Res. 67 (1) 289-299 (2007).
68. Wenzel U, Kuntz S, de Sansa UJ, Daneil H. Nitric oxide supresess apoptosis in human colon cancer cells by scavenging mitochondrial superoxide anions. Int. J. Cancercer 106(5), 666-675 (2003).
69. Gallo O, Masini E, Morbidelli L et al. Role of nitric oxide in angiogenesis and tumor progression in head and neck cancer. J. Natl Cancer Inst. 90, 587-596 (1998).
70. Janakiram BJ, Malisetty VS, Patlolla JM, Guruswamy S, Rao CV. A selective iNOS inhibitor NILT, suppress invasive colonic cancers and improves preventive efficacy of low dose COX-2 inhibitor, celecoxib in F344 rats. Presented at: American Association for Cancer Research 101st Annual meeting. Washington, DC, USA, 17-21 April 2010.
71. Kim SF, Huri DA, Snyder SH. Inducible nitric oxide synthase binds, S-nitrosylates, and activates cyclooxygenase-2. Science 310(5756), 1966-1970 (2005).
72. Caulin-Glaser T, García-Cardeña G, Sarrel P, Sessa WC, Bender Jr. 17b-estradiol regulation of human endothelial cell basal nitric oxide release, independent of cytosolic Ca2+ mobilization. Circ. Res. 81, 885-892 (1997).
73. Gratton JP, Fontana J, O'Connor DS, Garcia-Cardena G, McCabe TJ, Sessa WC. Reconstitution of an endothelial nitric-oxide synthase (eNOS), hsp90, and caveolin-1 complex in vitro. Evidence that hsp90 facilitates calmodulin stimulated displacement of eNOS from caveolin-1. J. Biol. Chem. 275, 22268-22272 (2000).
74. Chen DB, Bird IM, Zheng J, Magness RR. Membrane estrogen receptor-dependent extracellular signal-regulated kinase pathway mediates acute activation of endothelial nitric oxide synthase by estrogen in uterine artery endothelial cells. Endocrinology 145, 113-125 (2004).
75. Zhang H, Feng L, Livnat I et al. Estradiol-17b Stimulates specific receptor and endogenous nitric oxide-dependent dynamic endothelial protein S-nitrosylation: analysis of endothelial nitrosyl-proteome. Endocrinology 151(8), 3874-3887 (2010).
76. Leon-Bollotte L, Subramaniam S, Cauvard O et al. S-nitrosylation of the death receptor Fas promotes Fas ligand-mediated apoptosis in cancer cells. Gastroenterology 140, e4 (2011).
77. Hussain SP, Trivers GE, Hofseth LJ et al. Nitric oxide, a mediator of inflammation, suppresses tumorigenesis. Cancer Res. 64, 6849-6853 (2004).
78. Hussain SP, Amstad P, Raja K et al. Increased p53 mutation load in noncancerous colon tissue from ulcerative colitis: a cancer-prone chronic inflammatory disease. Cancer Res. 60, 3333-3337 (2000).
79. Reynaert NL, Ckless K, Korn SH et al. Nitric Oxide represess inhibitory kappaB Kinase through S-nitrosylation. Proc. Natl Acad. Sci. USA 101(24), 8945-8950 (2004).
80. DelaTorre A, Schroeder RA, Kuo PC. Alteration of NF-kappa B p50 DNA binding kinetics by S-nitrosylation. Biochem. Biophys. Res. Commun. 238(3), 703-706 (1997).
81. Scott DJ, Hull MA, Cartwright EJ et al. Lack of inducible nitric oxide synthase promotes intestinal tumorigenesis in the Apc(Min/+) mouse. Gastroenterology 121(4), 889-899 (2001).
82. Ambs S, Merriam WG, Ogunfusika MO et al. p53 and vascular endothelial growth factor regulate tumor growth of NOS2-expressing human carcinoma cells. Nat. Med. 4, 1371-1376 (1998).
83. Ropponen KM, Kellokoski JK, Lipponen PK et al. Expression of inducible nitric oxide synthase in colorectal cancer and its association with prognosis. Scand. J. Gastroenterol. 11, 1204-1211 (2000).
84. Kim SF, Huri DA, Snyder SH. Inducible nitric oxide synthase binds, S-nitrosylates, and activates cyclooxygenase-2. Science 310(5756), 1966-1970 (2005).
85. Hao XP, Pretlow TG, Rao JS, Pretlow TP. Inducible nitric oxide synthase is expressed similarly in multiple aberrant crypt foci and colorectal tumors from the same patients. Cancer Res. 61, 419-422 (2001).
86. Chhatwal VJ, Ngoi SS, Chan ST, Chia YW, and Moochhala SM. Aberrant expression of nitric oxide synthase in human polyps, neoplastic colonic mucosa and surrounding peritumoral normal mucosa. Cancinogenesis 15, 2081-2085 (1994).
87. Bing RJ, Miyataka M, Rich KA et al. Nitric oxide, prostanoids, cyclooxygenase and angiogenesis in colon and breast cancer. Clin. Cancer Res. 7, 3385-3392 (2001).
88. Roberts PJ, Riley GP, Morgan K, Miller R, Hunter JO, Middleton SJ. The physiological expression of inducible nitric oxide synthase in the human colon. J. Clin. Pathol. 54, 293-297 (2001).
89. Onier N, Hilpert S, Reveneau S et al. Expression of inducible nitric oxide synthase in tumors in relation with their regression induced by lipid S in rats. Int. J. Cancer. 81, 755-760 (1999).
90. Xie K, Huang S, Dong Z, Gutman M, Fidler IJ. Direct correlation between expression of endogenous inducible nitric oxide synthase and regression of M5076 reticulum cell sarcoma hepatic metastases in mice treated with liposomes containing lipopeptide CGP 31362. Cancer Res. 55, 3123-3131 (1995).
91. Kawamori T, Takahashi M, Watanabe K et al. Suppression of azoxymethane-induced colonic aberrant crypt foci by a nitric oxide synthase inhibitor. Cancer Lett. 148, 33-37 (2000).
92. Siegert A, Rosenberg C, Schmitt WD, Denkert C, Hauptmann S. Nitric oxide of human colorectal adenocarcinoma cell lines promotes tumor cell invasion. Br. J. Cancer. 86, 1310-1315 (2002).
93. Jenkins DC, Charles IG, Thomsen LL et al. Roles of nitric oxide in tumor growth. Proc. Natl Acad. Sci. USA 92, 4392-4396 (1995).
94. Xu W, Liu L, Charles IG. Microencapsulated iNOS-expressing cells cause tumor suppression in mice. FASEB J. 16, 213-215 (2002).
95. Scott DJ, Hull MA, Cartwright EJ et al. Lack of inducible nitric oxide synthase promotes intestinal tumorigenesis in the Apc(Min/+) mouse. Gastroenterology 121, 889-899 (2001).
96. Liu Q, Chan STF, Mhendran R. Nitric oxide induces cyclooxygenase expression and inhibits cell growth in colon cancer cell lines. Carcinogenesis 24, 637-642 (2003).
97. Buga GM, Wei LH, Bauer PM, Fukuto JM, Ignarro LJ. NG-hydroxy-l-arginine and nitric oxide inhibit Caco-2 tumor cell proliferation by distinct mechanisms. Am. J. Physiol. 275(4 Pt 2), R1256-R1264 (1998).
98. Mei JM, Hord NG, Winterstein DF, Donald SP, Phang JM. Expression of prostaglandin endoperoxide H synthase-2 induced by nitric oxide in conditionally immortalized murine colonic epithelial cells. FASEB J. 14, 1188-1201 (2000).
99. Jenkins DC, Charles IG, Thomsen LL et al. Roles of nitric oxide in tumor growth. Proc. Natl Acad. Sci. USA 92, 4392-4396 (1995).
100. Takahashi M, Fukuda K, Ohata T, Sugimura T, Wakabayashi K. Increased expression of inducible and endothelial constitutive nitric oxide synthases in rat colon tumors induced by azoxymethane. Cancer Res. 57, 1233-1237 (1997).
101. Rachmilewitz D, Stamler JS, Bachwich D, Karmeli F, Ackerman Z, Podolsky DK. Enhanced colonic nitric oxide generation and nitric oxide synthase activity in ulcerative colitis and Crohn's disease. Gut 36, 718-723 (1995).
102. Colon AL, Menchen L, Lizasoain I et al. Inducible nitric oxide synthase activity is expressed not only in inflamed but also in normal colonic mucosa in patients with ulcerative colitis: a potential prognostic marker. Am. J. Gastroenterol. 95, 1371-1373 (2000).
103. Hao XP, Pretlow TG, Rao JS, Pretlow TP. Inducible nitric oxide synthase (iNOS) is expressed similarly in multiple aberrant crypt foci and colorectal tumors from the same patients. Cancer Res. 61, 419-422 (2001).
104. Yagihashi N, Kasajima H, Sugai S et al. Increased in situ expression of nitric oxide synthase in human colorectal cancer. Virchows Arch. 436, 109-114 (2000).
105. Lagares-Garcia JA, Moore RA, Collier B, Heggere M, Diaz F, Qian F. Nitric oxide synthase as a marker in colorectal carcinoma. Am. J. Surg. 67, 709-713 (2001).
106. Szaleczky E, Pronai L, Nakazawa H, Tulassay Z. Evidence of in vivo peroxynitrite formation in patients with colorectal carcinoma, higher plasma nitrate/nitrite levels, and lower protection against oxygen free radicals. J. Clin. Gastroenterol. 30, 47-51 (2000).
107. Wan G, Kato N, Watanabe H. High fat diet elevates the activity of inducible nitric oxide synthase and 1,2-dimethylhydrazine-induced aberrant crypt foci in colon of rats. Oncol. Rep. 7, 391-395 (2000).
108. Dwyer MA, Bredt DS, Snyder SH. Nitric oxide synthase: irreversible inhibition by l-NG-nitroarginine in brain in vitro and in vivo. Biochem. Biophys. Res. Commun. 176, 1136-1141 (1991).
109. Rao C.V. Nitric Oxide signaling in colon cancer chemoprevention. Mut. Res. 555, 107-119. (2004).
110. Cianchi F, Cortesini C, Fantappie O, Messerini L. Inducible nitric oxide synthase expression in human colorectal cancer. Am. J. Pathol. 162, 793 (2003).
111. Landino LM, Crews BC, Timmons MD, Morrow JD, Marnett LJ. Peroxynitrite, the coupling product of nitric oxide and superoxide, activates prostaglandin biosynthesis. Proc. Natl Acad. Sci. USA 93, 15069-15074 (1996).
112. Salvemini D, Settle SL, Masferrer JL, Seibert K, Currie MG, Needleman P. Regulation of prostaglandin production by nitric oxide; an in vivo analysis. Br. J. Pharmacol. 114, 1171-1178 (1995).
113. Schleiffer R, Duranton B, Gossé F, Bergmann C, Raul F. Nitric oxide synthase inhibition promotes carcinogen-induced preneoplastic changes in the colon of rats. Nitric Oxide 4(6), 583-589 (2000).
114. Ridnour LA, Windhausen AN, Isenberg JS et al. Nitric oxide regulates matrix metalloproteinase-9 activity by guanylyl-cyclase-dependent and-independent pathways. Proc. Natl Acad. Sci. USA 104(43), 16898-16903 (2007).
115. Brinckerhoff CE, Rutter JL, Benbow U. Interstitial collagenases as markers of tumor progression. Clin. Cancer Res. 6(12), 4823-4830 (2000).
116. Huerta S, Chilka S, Bonavida B. Nitric oxide donors: novel cancer therapeutics Int. J. Oncol. 33, 909-927 (2008).
117. Rigas B, Kashfi K. Nitric-oxide-donating NSAIDs as agents for cancer prevention Trends Mol. Med. 10(7), 324-330 (2004).
118. Williams JL, Ping J, Nengtai O, Levy K, Rigas B. Protein nitration and nitrosylation by NO-donating aspirin in colon cancer cells: relevance to its mechanism of action. Exp. Cell Res. 317(10), 1359-1367 (2011).
119. Gratton JP, Lin MI, Yu J et al. Selective inhibition of tumor microvascular permeability by cavtratin blocks tumor progression in mice. Cancer Cell 4, 31-39 (2003).
120. Kashiwagi, S. Izumi Y, Gohongi T et al. NO mediates mural cell recruitment and vessel morphogenesis in murine melanomas and tissue-engineered blood vessels. J. Clin. Invest. 115, 1816-1827 (2005).
121. Jadfeski LC, Lala PK. Nitric oxide synthase inhibition by NG-nitro-l-arginine methyl ester inhibits tumor-induced angiogenesis in mammary tumors. Am. J. Pathol. 155, 1381-1390 (1999).
122. Kashiwagi S, Izumi Y, Gohongi T et al. NO mediates mural cell recruitment and vessel morphogenesis in murine melanomas and tissue-engineered blood vessels. J. Clin. Invest. 115, 1816-1827 (2005).
123. Wang G-Y, Ji B, Wang X, Gu J-H. Anti-cancer effect of iNOS inhibitor and its correlation with angiogenesis in gastric cancer. World J. Gastroenterol. 11(25), 3830-3833 (2005).
124. Chen T, Nines RG, Peschke SM, Kresty LA, Stoner GD. Chemopreventive effects of a selective nitric oxide synthase inhibitor on carcinogen-induced rat esophageal tumorigenesis. Cancer Res. 64, 3714-3717 (2004).
125. Janakiram NB, Mohammed A, Ravillah D et al. Chemoprevention of colon carcinogenesis in F344 rats by Se,Sé-1,4-phenylenebis(1,2-ethanediyl)bis- isoselenourea (PBISe) a novel analog of PBIT, an iNOS inhibitor. Cancer Prevent. Res. 3(Suppl. 1) A35 (2010).
126. Rao CV, Guruswamy S, Patlolla J, Janakiram N, Malisetty V. Chemoprevention of colon cancer by PBIT, an iNOS-selective inhibitor, administered alone or in combination with low-doses of celecoxib, a COX-2 selective inhibitor. Cancer Prevent. Res. 3(Suppl. 1) A53 (2010).
127. Rao CV, Malisetty SV, Cooma I, Reddy BS. Chemoprevention of familial adenomatous polyps and carcinomas by iNOS and COX-2 selective inhibitors administered individually, and in combination in the ApcMin-mice model. Proc. Am. Assoc. Cancer Res. 43, 670 (2002).
128. Thomsen LL, Scott JM J, Topley P, Knowles RG, Keerie A-J, Frend AJ. Selective inhibition of inducible nitric oxide synthase inhibits tumor growth in vivo: studies with 1400W, a novel inhibitor. Cancer Res. 57, 3300-3304, (1997).
129. Ziche M, Morbidelli L, Choudhuri R et al. Nitric oxide synthase lies downstream from vascular endothelial growth factor-induced but not basic fibroblast growth factor-induced angiogenesis. J. Clin. Invest. 99, 2625-2634 (1997).